When was zyprexa launched

Figure 3: Drug assessment summary for Zyprexa in bipolar disorder. Figure 5: Drug assessment summary of Zyprexa for schizophrenia. Figure 6: Drug assessment summary of Zyprexa for schizophrenia.

Table 1: Zyprexa bipolar disorder indication approvals. Table 3: Overview of key pivotal trial data for Zyprexa in bipolar disorder. Other risks include neuroleptic malignant syndrome, increased blood sugars, increased blood lipids, tardive dyskinesia, low blood pressure, white blood cell abnormalities, seizures, impaired judgment, and elevated prolactin levels.

Skip to main navigation. News Release Detail. May 14, Patients taking Symbyax should be monitored regularly for worsening of glucose control. Persons with diabetes who are started on atypicals should be monitored regularly for worsening of glucose control; those with risk factors for diabetes should undergo baseline and periodic fasting blood glucose testing. Undesirable alterations in lipids have been observed with Symbyax use.

Clinical monitoring, including baseline and follow-up lipid evaluations in patients using Symbyax, is advised. Significant, and sometimes very high, elevations in triglyceride levels have been observed with Symbyax use. Significant increases in total cholesterol have also been seen with Symbyax use. Potential consequences of weight gain should be considered prior to starting Symbyax. Patients receiving Symbyax should receive regular monitoring of weight. Symbyax may induce orthostatic hypotension associated with dizziness, tachycardia, bradycardia, and in some patients, syncope, especially during the initial dose-titration period.

Particular caution should be used in patients with known cardiovascular disease, cerebrovascular diseases, or those predisposed to hypotension.

If rash or other possibly allergic phenomena appear for which an alternative etiology cannot be determined, immediate discontinuation is recommended. As with all antipsychotic medications, a rare and potentially fatal condition known as NMS has been reported with olanzapine. The most common treatment-emergent adverse event associated with Symbyax in placebo-controlled clinical trials was somnolence.

Other common events were weight gain, increased appetite, asthenia, peripheral edema, tremor, pharyngitis, abnormal thinking, and edema. Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations.

Headquartered in Indianapolis, Ind. Additional information about Lilly is available at www. This press release contains forward-looking statements about Zyprexa R and Symbyax R. These statements reflect management's current beliefs; however, as with any commercial pharmaceutical product there are risks and uncertainties in the process of research and development and commercialization and regulatory review. Advanced search. Share Print Friendly. PME Digital Edition.